Christoph Baldegger, primary insider and member of the Board of Directors in
Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the
Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after
the share capital is registered, equal to approximately 0.92 % of the total
outstanding A-shares with voting rights.
For further information, contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)
This information is subject to the disclosure requirements in the Market Abuse
Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading
Act section 5-12.